| Article | Added |
|---|
| Senate backs PDUFA for pharma and device reviews | 05-24-12 |
| Sangart stashes $50M funding for oxygenation drugs | 05-24-12 |
| Pharma giants join forces on $285M antibiotics collaboration | 05-24-12 |
| MediciNova shares crash after lead asthma drug fails IIb trial | 05-24-12 |
| Celldex scores upbeat data for breast cancer drug | 05-24-12 |
| Upstart biotech lures Vertex founder out of retirement | 05-24-12 |
| J&J loses key FDA panel vote on Xarelto | 05-24-12 |
| European pharmas join forces on $285M antibiotics collaboration | 05-24-12 |
| Sanofi chief highlights high hopes for liver cancer drug | 05-24-12 |
| Halo garners support for PhII DMD study | 05-23-12 |
| GSK tweaks Human Genome bid to include poison pill antidote | 05-23-12 |
| The biggest R&D spenders in biotech | 05-23-12 |
| Novo confident that it can crack blockbuster oral insulin market | 05-23-12 |
| French biotechs afflicted by a plunge in financial support | 05-23-12 |
| InterMune deal delivers $55M in fresh fuel for fibrosis drug | 05-23-12 |
| Pharma VC embrace improves a biotech's chance of success | 05-23-12 |
| TheStreet: A roundup of the top drug studies left in 2012 | 05-22-12 |
| Study: Countries angling to lure U.S. biopharma companies | 05-22-12 |
| UPDATED: In rare slap, FDA review rips up Pfizer's case for tafamidis | 05-22-12 |
| Lilly posts clean safety data on PhIII diabetes blockbuster hopeful | 05-22-12 |
| Biotechs raise new VC rounds to back inhalable drugs, antimicrobials | 05-22-12 |
| Takeda shutters Bay Area R&D shop in California shakeup | 05-22-12 |
| Mohr Davidow's Siegel tapped to run $6B GE health tech initiative | 05-21-12 |
| New study confirms worst fears about Merck's HIV vaccine | 05-21-12 |
| Three new rules for biopharma collaborations | 05-21-12 |
| iPierian salvages new game plan after stem cell tech loses its sizzle | 05-21-12 |
| FDA staff backs J&J's Xarelto for heart condition | 05-21-12 |
| AstraZeneca pulling out all stops in R&D deal frenzy | 05-21-12 |
| User fee legislation promises better access, speedier reviews at FDA | 05-21-12 |
| UPDATED: New cloud hovers over class of 'good cholesterol' drugs | 05-18-12 |
| Massachusetts plants seed for new biotech destination | 05-18-12 |
| The R&D revolution wants you | 05-18-12 |
| Cancer Genetics' IPO delayed amid Facebook frenzy | 05-18-12 |
| Kleiner Perkins to back early-stage biotechs with $525M fund | 05-18-12 |
| New cloud hovers over class of 'good cholesterol' drugs | 05-18-12 |
| Allergan to enlist new hires in R&D expansion | 05-17-12 |
| Canada hands Osiris historic approval for stem-cell drug | 05-18-12 |
| Study: FDA outpaces the EMA on drug reviews, new approvals | 05-17-12 |
| Kythera files $86M IPO to support fat-busting drug | 05-17-12 |
| HGS faces skeptics as it boasts of a crowded bargaining table | 05-17-12 |
| UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects | 05-17-12 |
| GSK lands one-two punch in melanoma trial | 05-17-12 |
| Piramal bets on pharma's data binging in $635M buyout | 05-16-12 |
| UPDATED: Upstart Ra sheds stealth status, targets new drug class | 05-16-12 |
| Cancer drug experts brace for ASCO abstract dump tonight | 05-16-12 |
| Elevation boasts 'gold standard' IIb data for COPD therapy | 05-16-12 |
| Achillion burnishes buyout prospects, snags fast track for hep C drug | 05-16-12 |
| Ra sheds stealth status, targets HAE with VC cash | 05-16-12 |
| Genentech drug picked for pioneering $100M Alzheimer's trial | 05-15-12 |
| Newron soars on positive PhIII results, $26M pact for Parkinson's drug | 05-15-12 |
| First wave of AstraZeneca's CNS R&D group gets the ax | 05-15-12 |
| New chief takes helm at Promedior and steers a course for Boston | 05-15-12 |
| Buzz: Big Pharma suitors line up for a look at Amylin's books | 05-15-12 |
| Download our eBook 'Supplying global clinical trials: Keys to avoiding costly delays' | 05-14-12 |
| GSK snags proteomics platform tech in $98M Cellzome buyout | 05-15-12 |
| Serono workers plot strike, lash out over R&D failures | 05-14-12 |
| Lundbeck soars on PhIII success for blockbuster hopeful | 05-14-12 |
| Cancer drug developers angling for center stage at ASCO | 05-14-12 |
| OncoMed offers $115M IPO bet on cancer stem cell work | 05-14-12 |
| Big Pharma's high-risk pursuit of CNS gold faces major market doubts | 05-14-12 |
| FDA panel OKs Gilead's key HIV drug Quad | 05-11-12 |
| Burrill: Big Pharma's academic tie-ups are 'nuts' | 05-11-12 |
| Incyte rides wave after Pfizer's FDA panel nod | 05-11-12 |
| Amgen pushes agenda for biosimilars on the FDA | 05-11-12 |
| Indian gov't probes drug regulator after scathing review | 05-11-12 |
| UPDATED: Arena Pharma's weight drug wins the day, shares soar | 05-10-12 |
| Google's Brin allies with Pfizer and GSK in war on Parkinson's | 05-11-12 |
| Arena Pharma's weight drug wins the day | 05-10-12 |
| Rib-X Pharma delays IPO after price halved | 05-10-12 |
| All eyes in the biotech world on Arena's diet pill | 05-10-12 |
| Biotech startup Egalet lassos $14.3M B round, new CEO | 05-10-12 |
| Subpar clinical trials probed in India's review of regulation | 05-10-12 |
| Biotech ?gambler? Blech loses big in securities scam | 05-10-12 |
| UPDATED: FDA advisers sign off on Pfizer's arthritis pill | 05-09-12 |
| Third Rock's Levin calls for teamwork in personalized medicine | 05-09-12 |
| Early VC rounds nosedive for biotech startups in Q1 | 05-09-12 |
| FDA details kidney damage in Gilead's Quad studies | 05-09-12 |
| Stem cell therapy rescues child with marrow disease | 05-09-12 |
| FDA advisers snub Regeneron drug for gout | 05-09-12 |
| Support seen for U.S. plan to speed nods for 'breakthrough' drugs | 05-09-12 |
| GSK raises fists in $2.6B hostile bid for Human Genome Sciences | 05-09-12 |
| FDA withdraws hold on GTx's prostate cancer drug | 05-08-12 |
| UPDATED: Arena shares up after FDA briefing on lorcaserin | 05-08-12 |
| Ex-Sanofi chemist locked up after theft | 05-08-12 |
| Arena shares up after FDA briefing on lorcaserin | 05-08-12 |
| Talon sinks after FDA prolongs cancer drug review | 05-08-12 |
| Amgen, VC groups pump $16.5M into Sutro Biopharma | 05-08-12 |
| Eleven adds $20M in venture cash as it preps for the clinic | 05-08-12 |
| UPDATED: Vertex sizzles with upbeat PhII data on combo therapy for cystic fibrosis | 05-07-12 |
| Lilly Ventures-backed startup grabs $4.6M round | 05-07-12 |
| Insmed stock soars after FDA ends hold on key lung drug | 05-07-12 |
| Novartis passes Phase III test for rare-disorder drug | 05-07-12 |
| FDA harps on risks of Pfizer's tofacitinib as panel looms | 05-07-12 |
| Vertex sizzles with upbeat PhII data on combo therapy for cystic fibrosis | 05-07-12 |
| Roche abandons potential blockbuster cholesterol drug | 05-07-12 |
| FDA notes cancer cases linked to Regeneron gout drug | 05-04-12 |
| NIH, U.S. agencies pay for nearly half of global health R&D | 05-04-12 |
| Bill calls for cancer clinical trials results to be reported--or else | 05-04-12 |
| Investors pocket $761M in deal betting on Biogen's BG-12 | 05-04-12 |
| FDA whacks Alexza Pharma with CRL for Adasuve | 05-04-12 |
| Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib | 05-04-12 |
| Pharma giants offer up drug candidates for $20M NIH collaboration | 05-03-12 |
| GSK chief rules out AstraZeneca buyout | 05-03-12 |
| Abbott hits the sweet spot, pays $110M cash for PhIIb drug | 05-03-12 |
| Crazy or creative? MIT finance whiz suggests a twist on CDOs for R&D | 05-03-12 |
| Pressure on premiums in M&A push biotech prices higher | 05-03-12 |
| Idera's troubled TLR program founders in PhII cancer study | 05-03-12 |
| Lundbeck banks on pipeline as antidepressant sales skid | 05-02-12 |
| Lilly invests £5.4M in R&D hub in U.K. | 05-02-12 |
| Aveo Pharma flunks Phase II lung cancer study | 05-02-12 |
| Pfizer scouts for bite-sized buyouts after Lipitor sales wilt | 05-02-12 |
| Savient hammered after hedge fund claims it's bankrupt | 05-02-12 |
| FDA OK for Gaucher drug opens new market for Pfizer, Protalix | 05-02-12 |
| Pfizer turns to late-stage pipeline to make up for Lipitor crash | 05-01-12 |
| Growing Novo Nordisk inks $100M tech deal, boasts of blockbuster hopefuls | 05-01-12 |
| AstraZeneca's new iMed R&D team forges first pact with Axerion | 05-01-12 |
| AZ's new iMed R&D team forges first pact with Axerion | 05-01-12 |
| GSK development team tackles a new drug class at Yale | 05-01-12 |
| Supernus IPO spotlights perils, potential of going public | 05-01-12 |
| Brennan's golden handshake could total $65M | 04-30-12 |
| VC group offers to help axed Merck KGaA staffers launch spinoffs | 04-30-12 |
| 2012: Year of the dealmaker in biopharma | 04-30-12 |
| Actelion surges as positive PhIII macitentan data reignites buyout buzz | 04-30-12 |
| Biotech venture rounds dwindle in Europe, tracking U.S. trend | 04-30-12 |
| Vivus gets ED drug approval, spurring fresh talk of a deal | 04-27-12 |
| Vivus gets first approval, spurring fresh talk of a deal | 04-27-12 |
| UPDATED: Novo Nordisk hiring R&D, other workers in U.S. recruitment blitz | 04-27-12 |
| Bristol turns to blockbuster pipeline as Plavix goes generic | 04-27-12 |
| Pfizer stays in the autism drug chase | 04-27-12 |
| Astellas, biotech VCs to pump $14M into virtual drug developer | 04-27-12 |
| Jazz Pharma snaps up Eusa in $700M buyout deal | 04-27-12 |
| Novo Nordisk hiring R&D, other workers in U.S. recruitment blitz | 04-27-12 |
| FDA stamps approval on GSK cancer drug Votrient | 04-27-12 |
| Takeda rebuffed (again) in long quest for FDA drug OK | 04-26-12 |
| Repligen shares tank on expected FDA rejection | 04-26-12 |
| PRA snags Amgen's PhIII biosimilars contract | 04-26-12 |
| Brennan's ouster at AstraZeneca sets stage for big changes in R&D | 04-26-12 |
| Epizyme builds epigenetics lineup with $90M Celgene score | 04-25-12 |
| Buzz: Is Bayer looking to buy Onyx Pharma? | 04-25-12 |
| Advocacy groups launch new services to match patients and trials | 04-25-12 |
| GSK and HGS posture over price and value in M&A standoff | 04-25-12 |
| Oregano attacks prostate cancer cells in lab experiment | 04-25-12 |
| Scrambling to add new drugs, Big Pharma is paying big premiums for biotechs | 04-25-12 |
| The Biggest R&D Spenders in Biopharma | 04-25-12 |
| Sanofi's Lemtrada beats Rebif in head-to-head MS showdown | 04-25-12 |
| Targacept slashes staff by half in wake of PhIII disaster | 04-25-12 |
| Merck KGaA shuttering Swiss complex, dispatching R&D to Boston | 04-24-12 |
| Amgen founding CEO George Rathmann dies at 84 | 04-24-12 |
| Biogen Idec builds blockbuster case for new MS drug BG-12 | 04-24-12 |
| Argos and miRagen add new venture rounds to back R&D efforts | 04-24-12 |
| AstraZeneca plots more pipeline deals | 04-24-12 |
| Merck KGaA shuttering Swiss complex, dispersing R&D staffers to Boston and Beijing | 04-24-12 |
| Analysts buzz over new Amgen CEO's plans for $20B cache | 04-24-12 |
| Biota plots U.S. move in Nabi Bio merger | 04-23-12 |
| PolyMedix shares slide on report of positive Phase II antibiotic data | 04-23-12 |
| Pike picked to sit at Quintiles peak | 04-23-12 |
| Buzz: Amylin brings in the bankers to spur an auction | 04-23-12 |
| AstraZeneca reels in promising Phase III gout drug in $1.26B Ardea buyout | 04-23-12 |
| Biotech VC deals, dollars shrivel in Q1 as devices see an upturn | 04-23-12 |
| AstraZeneca reels in promising PhIII gout drug in $1.26B Ardea buyout | 04-23-12 |
| Alnylam scores efficacy data with PCSK9 drug | 04-20-12 |
| Lack of Gilead and BMS teamwork on hep C draws ire | 04-20-12 |
| European committee backs AZ, BMS and Novartis drugs for approval | 04-20-12 |
| FDA hits brakes on Novartis' hep C program after death | 04-20-12 |
| Merck KGaA chief swears off major deals amid pipeline woes | 04-20-12 |
| Readers' picks, responses to Fierce's 'Top 10' cancer drugs report | 04-20-12 |
| Elan chases a holy grail of Alzheimer's treatment: Prevention | 04-19-12 |
| UPDATED: Cell Therapeutics lands myelofibrosis drug with $30M upfront | 04-19-12 |
| Fox Foundation partners with Sanofi on Parkinson's study | 04-19-12 |
| Adimab adds Gilead pact to its growing roster of antibody deals | 04-19-12 |
| Gilead wows analysts as 7977 combos quell hep C in most patients | 04-19-12 |
| UPDATED: GSK puts Human Genome Sciences in play with $2.59B buyout offer | 04-19-12 |
| GSK puts Human Genome Sciences in play with $2.59B buyout offer | 04-19-12 |
| Alder broadens antibody work with $38M D round | 04-19-12 |
| UPDATED: Crucell and Royal DSM pull the plug on biosimilar JV | 04-18-12 |
| Abbott touts positive Parkinson's Phase III as pharma split looms | 04-18-12 |
| Biopharma giants call on FDA to demand tough standards for biosimilars | 04-18-12 |
| Top 10 late-stage cancer drugs in 2012 | 04-18-12 |
| J&J and Bristol-Myers ally on another potential hep C blockbuster | 04-18-12 |
| 10 promising late-stage cancer drugs in 2012 | 04-18-12 |
| Roche says it won't extend Illumina offer past Friday deadline | 04-18-12 |
| GSK doubles down on FivePrime drug discovery collaboration | 04-18-12 |
| Crucell and Royal DSM pull the plug on biosimilar JV | 04-18-12 |
| Addex axes 28 in wake of positive Parkinson's drug study | 04-17-12 |
| UC San Diego blueprints $110M R&D collaboration complex | 04-17-12 |
| Aveo on a hiring spree as it preps for the launch of tivozanib | 04-17-12 |
| Ono's oral MS drug eliminates brain lesions in promising Phase II study | 04-17-12 |
| Tech visionary Thiel sets out to spark a biotech revolution | 04-17-12 |
| Ono's oral MS drug eliminates brain lesions in promising PhII study | 04-17-12 |
| Third Rock, biotech VCs make baby formula gambit | 04-17-12 |
| Piramal lays claim to a late-stage imaging rival for Lilly's Alzheimer's agent | 04-16-12 |
| A DIY clinical study? Desperate patients try a therapeutic 'home brew' | 04-16-12 |
| Halozyme shares plunge on FDA rejection | 04-16-12 |
| Samsung plans ambitious rollout of biosims at deep discounts | 04-16-12 |
| Hyperion joins the growing IPO queue with $57M offering | 04-16-12 |
| Merck snags rights to Endocyte's ovarian cancer drug in $1B deal | 04-16-12 |
| UPDATED: Sanofi CEO touts partnership drugs as pipeline standouts | 04-13-12 |
| Sanofi CEO touts partnership drugs as pipeline standouts | 04-13-12 |
| Google VC eyes biotech in data analytics push | 04-13-12 |
| UPDATED: Tioga nabs $10M VC deal amid PhIII for bowel disorder drug | 04-12-12 |
| Lilly CEO avoids Pfizer-like cuts, focuses on pipeline | 04-13-12 |
| Embattled AZ chief: Bigger R&D bets, megadeals not the answer | 04-13-12 |
| UPDATED: Biopharma lobby members pumped $49.5B into R&D | 04-13-12 |
| Tioga nabs $10M VC deal amid PhIII for bowel disorder drug | 04-12-12 |
| Supernus plots product launches as it dusts off $76M IPO attempt | 04-12-12 |
| NIH chief preps pact to revive shelved drug programs | 04-12-12 |
| GSK turns to Chiome for antibody discovery | 04-12-12 |
| Shire picks up Pervasis in potential $200M deal | 04-12-12 |
| Gilead's blockbuster hep C gamble takes center stage at EASL | 04-12-12 |
| Halo takes the virtual approach to developing a DMD treatment | 04-12-12 |
| Cetero execs look for a silver lining in bankruptcy sale | 04-11-12 |
| U.K. officials ready $286M fund to fuel a biotech revival | 04-11-12 |
| Cetero execs look for a silver lining in bankruptcy auction | 04-11-12 |
| Vertex chief earned $13.4M in '11 | 04-11-12 |
| RNAi developer Arrowhead snags startup Alvos in stock deal | 04-11-12 |
| Dendreon vets grab the helm of a troubled vaccine developer | 04-11-12 |
| Threshold Pharma lands $20M milestone from Merck KGaA | 04-11-12 |
| Vivus shares slide as FDA delays decision on Qnexa | 04-10-12 |
| UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout | 04-10-12 |
| Affymax banks $50M milestone on ESA drug approval | 04-10-12 |
| Amgen snags KAI Pharma's CKD program in $315M buyout | 04-10-12 |
| Merck, Flagship join forces on fostering biotech startups | 04-10-12 |
| Icahn sues Amylin in hopes a proxy fight will trigger sale | 04-10-12 |
| H.I.G. unveils a $268M fund dedicated to biotech | 04-09-12 |
| FT: AstraZeneca investors turn up the heat under CEO Brennan | 04-09-12 |
| Analysts pounce on positive Phase II data on hep C combo | 04-09-12 |
| Optimer ousts chairman, top execs over a grant of shares in affiliate | 04-09-12 |
| Novartis researchers discover promising arthritis molecule | 04-09-12 |
| Lilly gains FDA approval for its controversial brain plaque test | 04-09-12 |
| Bristol stays in hunt for Amylin | 04-06-12 |
| Astellas scores FDA panel nod for overactive bladder drug | 04-06-12 |
| Time for a three-day weekend | 04-05-12 |
| Biocon hiring 300 scientists for new R&D complex in India | 04-05-12 |
| Cleveland BioLabs shares tank after BARDA drops support | 04-05-12 |
| Biotech vets back $22M A round for neuroscience startup | 04-05-12 |
| Sanofi colorectal cancer contender Zaltrap suffers a PhIII trial setback | 04-05-12 |
| Spectrum nabs Allos buyout as bladder cancer drug fails PhIII | 04-05-12 |
| Industry Voices: The Fibrosis Stampede | 04-04-12 |
| Biogen Idec bets it can succeed on a risky Phase III ALS gamble | 04-04-12 |
| Abbott wows the crowd with promising Phase II hep C data | 04-04-12 |
| Icahn goes in for the kill at Amylin | 04-04-12 |
| Nanomedicine standout spotlights first human cancer data | 04-04-12 |
| Biogen Idec bets it can succeed on a risky PhIII ALS gamble | 04-04-12 |
| Billions in new venture cash targeted at early-stage biotech efforts | 04-04-12 |
| AstraZeneca scouts new drug deals to silence a chorus of critics | 04-04-12 |
| OvaScience grabs $37M B round for fertility treatments | 04-03-12 |
| Traditional Chinese medicine team preps for Phase II cancer study | 04-03-12 |
| High-profile investigator tapped to lead $10M prostate cancer program | 04-03-12 |
| Stemline bets $50M IPO on a pair of cancer stem cell treatments | 04-03-12 |
| Google contributes to $14M round for fast-growing Adimab | 04-03-12 |
| Bayer bolsters blockbuster case for regorafenib with new PhIII data | 04-03-12 |
| UPDATED: AstraZeneca pays $50M to partner up on Amgen antibodies | 04-02-12 |
| AstraZeneca pays $50M to partner up on Amgen antibodies | 04-02-12 |
| Keryx, Aeterna shares crater on word of Phase III cancer study flop | 04-02-12 |
| AstraZeneca pays $50 million to partner up on Amgen antibodies | 04-02-12 |
| Novartis posts promising Phase III results for blockbuster hopeful QVA149 | 04-02-12 |
| Lundbeckfond contributes to $25M B round for AlloCure's Phase II stem cell study | 04-02-12 |
| GSK's Witty calls for joint effort on antibiotic development | 04-02-12 |
| UPDATED: Roche readies for approvals of previously snubbed breast cancer drug | 03-30-12 |
| Merrimack Pharma stumbles out of the IPO gate | 03-30-12 |
| PhIII failure blights Shire's effort to crack new market for bowel drug | 03-30-12 |
| FDA panel favors added cardio studies for risky weight drugs | 03-30-12 |
| Ex-Amgen drug researcher calls out questionable cancer findings | 03-30-12 |
| Provenge critic gaining attention after taking shots at study data | 03-30-12 |
| Keryx, Aeterna shares crater on word of Phase III cancer study failure | 04-02-12 |
| Tokai unveils promising Phase I data for 'triple whammy' prostate cancer contender | 04-02-12 |
| Check out the new and improved FierceBiotech.com | 03-30-12 |
| AVI tanks after positive PhIIb fails to improve outcomes for DMD | 04-02-12 |
| UPDATED: FDA rejects Chelsea's Northera, demands additional study data | 03-28-12 |
| Optimer inks $90M C. difficile drug pact with Astellas | 03-29-12 |
| Amgen, Lilly turn in upbeat data on rival psoriasis drugs | 03-29-12 |
| Cetero preps for new owner after filing for bankruptcy protection | 03-29-12 |
| Is an Amylin takeover inevitable after the BMS rejection? | 03-29-12 |
| VC boom: U.K. charity births $80M biotech fund for cancer drug research | 03-29-12 |
| FDA rejects Chelsea's Northera, demands additional study data | 03-28-12 |
| Merrimack Pharma discounts expectations in $100M IPO | 03-28-12 |
| Moscow backs clones of Western biotech programs in Russia | 03-28-12 |
| UPDATED: Amylin shares rocket up on report of $3.5B buyout offer by Bristol-Myers | 03-28-12 |
| Promethera Biosciences banks $31M to fund PhI/II stem cell trial | 03-28-12 |
| Novartis leads $12.5M A round for antibody diagnostics start-up ImaginAb | 03-28-12 |
| Amylin shares rocket up on report of $3.5B buyout offer by Bristol-Myers | 03-28-12 |
| Conflicting signals cloud Chelsea's chances on D-Day for Northera | 03-28-12 |
| Affymax breaks Amgen's anemia drug monopoly with ESA approval | 03-27-12 |
| Lawmakers push for speedy approvals of 'breakthrough' drugs | 03-27-12 |
| Biogen executive team rakes in millions from its 2011 successes | 03-27-12 |
| Targacept scuttles diabetes drug program in fresh setback | 03-27-12 |
| Bausch & Lomb snags experimental eye treatments in $500M ISTA buyout | 03-27-12 |
| UPDATED: FDA stiff-arms Map's app for migraine therapy Levadex | 03-27-12 |
| Tesaro promises rapid progress with cancer drugs in $86M IPO | 03-26-12 |
| Sanofi, Regeneron report stellar LDL drug data as race heats up | 03-26-12 |
| Fierce's Top 10 Biotech techies | 03-26-12 |
| FDA accusations of 'corrupt' lab practices push Cetero into bankruptcy | 03-26-12 |
| Amgen CEO's retirement pay could register at $49M | 03-26-12 |
| Bleeding risk clouds Merck's hopes for vorapaxar franchise | 03-26-12 |
| FDA accusations of "corrupt" lab practices push Cetero into bankruptcy | 03-26-12 |
| Private equity player pumping $50M into cancer drug startup | 03-26-12 |
| Amgen's LDL blockbuster hopeful wows with impressive efficacy data | 03-25-12 |
| UPDATED: GSK, Theravance share mixed bag of lung drug data ahead of FDA filing | 03-23-12 |
| Durata, with license to Pfizer drug, lays plans for $86M IPO | 03-23-12 |
| Merck backs big VC plan in Canada | 03-23-12 |
| Depression drug research goes off the rails (again) | 03-23-12 |
| UPDATED: Addex surges on upbeat data from Parkinson's drug trial | 03-23-12 |
| $110M therapeutics center on tap for UC San Diego campus | 03-23-12 |
| GSK, Theravance share mixed bag of lung drug data ahead of FDA filing | 03-23-12 |
| Addex surges on upbeat data from Parkinson's drug trial | 03-23-12 |
| UPDATED: Merck drug homes in on new baldness target | 03-22-12 |
| Pozen shares jump on promising outcome for PhIII studies | 03-22-12 |
| Pozen shares jump on promising outcome for Ph3 studies | 03-22-12 |
| Merck drug homes in on new baldness target | 03-22-12 |
| Developers spotlight huge potential of new class of cholesterol drugs | 03-22-12 |
| Big Pharma entry's new name, AbbVie: rhymes with R&D | 03-22-12 |
| Growing popularity of virtual biotechs promises boon to outsourcers | 03-22-12 |
| New drug for rare leukemia wins FDA panel vote with limited data | 03-22-12 |
| A rare leukemia drug wins FDA panel vote with limited data | 03-22-12 |
| UPDATED: Cytos revives lead program in $40M financing deal with Amgen, venBio | 03-21-12 |
| J&J unit to pay $8.7M to Galapagos for drug candidate | 03-21-12 |
| NicOx eyes global status in eye drug game with up to $30.9M buyout of Altacor | 03-21-12 |
| Amarin jumps on positive patent news for blockbuster hopeful | 03-21-12 |
| NicOx eyes global status in eye drug game with up to $30.9M buyout of Altcor | 03-21-12 |
| FDA panel shoots down Merck/Ariad cancer drug as GSK marches on | 03-21-12 |
| Cytos revives lead program in $40M financing deal with Amgen, venBio | 03-21-12 |
| GSK, J&J back Index's new $200M fund for early-stage deals | 03-21-12 |
| Pfizer faces bumps in road with potential blockbuster RA pill | 03-20-12 |
| Nektar boosts R&D presence in San Francisco | 03-20-12 |
| New $317M biotech fund takes off at Wellcome Trust | 03-20-12 |
| U.K. green lights study of pioneering gene therapy against cystic fibrosis | 03-20-12 |
| Shire snaps up CNS program from startup Heptares, commits $190M in 'biobucks' | 03-20-12 |
| Virtual is beautiful in biotech | 03-20-12 |
| Final PhIII results wipe out AstraZeneca, Targacept depression drug | 03-20-12 |
| Final Ph3 results wipe out AstraZeneca, Targacept depression drug | 03-20-12 |
| Ampio Pharma shares soar after upbeat update on eye drug | 03-19-12 |
| VC dollars flowing into Europe | 03-19-12 |
| Cardiome whips out budget ax as Merck dumps oral heart drug pact | 03-19-12 |
| Roche headlines autism alliance | 03-19-12 |
| Anthera slashes jobs over failed cardiac trial, shifts focus to lupus drug | 03-19-12 |
| At the threshold of PhIII, Neurologix heads into bankruptcy | 03-19-12 |
| Don't let the past obscure your future | 03-19-12 |
| Amarin stock jumps on patent progress for blockbuster hopeful; OncoGenex seeks $46.8M in stock sale; | 03-16-12 |
| Novartis grabs rights to eye drug in $494M deal | 03-16-12 |
| Sanofi beefs up former Genzyme unit with Pluromed buyout | 03-16-12 |
| After slashing jobs, Pfizer CEO Ian Read draws $25M | 03-16-12 |
| FDA questions benefit of Merck and Ariad's bone cancer drug | 03-16-12 |
| VCs rally behind Tarsa Therapeutics in $28M B round | 03-16-12 |
| Active Biotech gets boost from late-stage oral MS program | 03-16-12 |
| Shire yanks BLA for Fabry treatment in surprise about-face | 03-15-12 |
| Biogen Idec strikes $34M option pact with MAKScientific | 03-15-12 |
| UPDATED: Merck offers $90M to bankroll new drug discovery institute | 03-15-12 |
| Sofinnova preps Irish venture plans with $37.5M in fresh support | 03-15-12 |
| Merck offers $90M to bankroll new drug discovery institute | 03-15-12 |
| Did Big Pharma scuttle an attempt to radically restructure the approval pathway? | 03-15-12 |
| Shire nabs Bay Area's FerroKin, orphan drug in $325M buyout | 03-15-12 |
| Your name here: Max Planck Florida shops naming rights for $10M | 03-14-12 |
| Okairos launches pioneering mid-stage study of promising hep C vaccine | 03-14-12 |
| Marina inks $14M discovery pact with ProNAi | 03-14-12 |
| Animal rights groups in U.K. blockade supply routes for researchers | 03-14-12 |
| Langer upstart rakes in fresh venture cash for mucus-targeting drugs | 03-14-12 |
| Sir Chris Evans inspires creation of a £100M Welsh biotech fund | 03-14-12 |
| Omeros touts promising PhIII for ophthalmology treatment | 03-13-12 |
| Regulators start thinking creatively about new approval pathway | 03-13-12 |
| NicOx spikes on successful glaucoma drug study | 03-13-12 |
| FDA scientists see improved integrity, but complaints of interference still common | 03-13-12 |
| FDA panel backs effort to lift class hold on anti-NGF pain drugs | 03-13-12 |
| Pfizer walks away from $350M insulin pact with India's Biocon | 03-13-12 |
| Disappointing cancer data triggers sharp drop in Peregrine shares | 03-12-12 |
| Bionovo slashes bulk of staff, cuts costs as cash runs out | 03-12-12 |
| HemaQuest nails $13M VC extension for sickle cell program | 03-12-12 |
| Bionovo slashes bulk of staff, cuts costs on cash crunch | 03-12-12 |
| Pfizer spearheads push to get pain drugs back on blockbuster track | 03-12-12 |
| Tranzyme shares implode as lead GI drug flunks its PhIII closeup | 03-12-12 |
| Anthera shares collapse on halt of Phase III cardio trial | 03-12-12 |
| Anthera shares collapse on halt of Ph3 cardio trial | 03-12-12 |
| UPDATED: Teva, OncoGenex amp up Phase III fight against prostate cancer | 03-09-12 |
| FDA nudged to treat antibiotics like rare disease drugs | 03-09-12 |
| AstraZeneca nears bundle of buyouts to feed ailing pipeline | 03-09-12 |
| Aastrom banks $38M for pivotal study of cellular therapy | 03-09-12 |
| Teva, OncoGenex amp up Phase III fight against prostate cancer | 03-09-12 |
| Big trouble seen for targeted cancer drugs | 03-09-12 |
| Merck cancer drug digs into HIV's last hiding places | 03-09-12 |
| 'Dateline' exposé snares Indian CROs in an ethics 'sting' | 03-08-12 |
| Bellicum snags $20M for mid-stage cancer vaccine program | 03-08-12 |
| Gilead spotlights key details from pivotal Quad study | 03-08-12 |
| J&J wows analysts with early success of Zytiga PhIII for prostate cancer | 03-08-12 |
| NeurogesX slashes staff, shifts R&D direction after FDA slaps down app | 03-08-12 |
| J&J wows analysts with early success of Zytiga Ph3 for prostate cancer | 03-08-12 |
| Promedior lands $21.5M D round for fibrosis pipeline | 03-07-12 |
| CNS drug developers face long stretch in the clinic, poor odds of success | 03-07-12 |
| Positive Phase III sets stage for levomilnacipran NDA | 03-07-12 |
| Fresh woes for Gilead as two more hep C patients relapse in small 7977 study | 03-07-12 |
| Mersana snaps up $270M cancer drug deal with Endo Pharma | 03-07-12 |
| Tufts: CNS drug developers face long stretch in the clinic, poor odds of success | 03-07-12 |
| Discovery Labs shares rocket up on long-awaited FDA approval | 03-07-12 |
| OpGen bags up to $17M in VC deal | 03-07-12 |
| UPDATED: Aragon raises $42M for closely-watched prostate cancer drug | 03-05-12 |
| Abcam's $155M Epitomics buyout expands antibody business | 03-06-12 |
| Our collaboration with BioWorld Today | 03-06-12 |
| Top 10 VC medical device deals H2 2011 | 03-06-12 |
| Aegerion application for lead rare disease drug lands at FDA | 03-06-12 |
| Oncothyreon shares routed as Stimuvax PhIII trial soldiers on | 03-06-12 |
| Domain partners with RusNano on $760M biotech investment plan | 03-06-12 |
| Aragon raises $42M for closely-watched prostate cancer drug | 03-05-12 |
| Company 'insiders' left with 43% of Verastem's shares | 03-05-12 |
| PhIII placebo response complicates Lundbeck's case for anti-drinking drug | 03-05-12 |
| Merck plans NDA on promising Phase III data for allergy pill | 03-05-12 |
| FDA rejects Merck's new combo cholesterol drug | 03-05-12 |
| SciClone dumps cancer drug after failed IIb | 03-05-12 |
| FDA rejects Merck's new combo cholesterol drug | 03-05-12 |
| Fledgling 4s3 garners $20M for rare disease work | 03-05-12 |
| Company 'insiders' nabbed 43% of Verastem's IPO offering | 03-05-12 |
| High Ph3 placebo response complicates Lundbeck's case for anti-drinking drug | 03-05-12 |
| Roche arthritis drug beats Humira in clinical study | 03-02-12 |
| Gov't advisor calls on FDA to boost clinical trials of drugs in kids | 03-02-12 |
| Ex-Amgen R&D chief Perlmutter in talks with other companies about next move | 03-02-12 |
| Columbia Labs axing 42% of jobs after FDA shoots down drug application | 03-02-12 |
| Bioethicist quits job at controversial stem cell outfit | 03-02-12 |
| Novartis cancer drugs stymie deadly Ebola virus | 03-02-12 |
| GSK and Daiichi create joint development venture in Japan | 03-01-12 |
| Key to IPO success: recruiting 'insiders' who will buy into the offering | 03-01-12 |
| Pfizer, BMS face a delay on FDA's megablockbuster decision on apixaban | 03-01-12 |
| Parkinson's drug combats disability after major brain injuries | 03-01-12 |
| Elan CEO puts retirement party on hold as Alzheimer's PhIII looms | 03-01-12 |
| GSK and Daiichi create new vaccine joint development venture in Japan | 03-01-12 |
| Elan CEO puts retirement party on hold as Alzheimer's PhIII looms | 03-01-12 |
| Dutch antibody experts forge rare disease discovery pact with Shire | 02-29-12 |
| C3 Jian raises $30M for dental treatment | 02-29-12 |
| Vivus basks in limelight of rampant M&A speculation | 02-29-12 |
| Abbott's deal-team delivers $1.35B Galapagos RA pact | 02-29-12 |
| Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout | 02-29-12 |
| Concert Pharma snags $200M licensing pact with Avanir | 02-29-12 |
| Forest, Gedeon trumpet fresh Phase III successes for antipsychotic pill | 02-28-12 |
| Can an herbal medicine provide the key to defeating Alzheimer's? | 02-28-12 |
| Bayer CEO Dekkers says price cuts threaten R&D | 02-28-12 |
| The dream of human immortality tonics lives on--in worms | 02-28-12 |
| BMS amps up academic partnerships with PhII project at Duke | 02-28-12 |
| Biogen Idec races to FDA and EMA with a blockbuster app for BG-12 | 02-28-12 |
| Shanghai-based CRO Newsummit outlines $80M IPO | 02-27-12 |
| BioSante shares surge on GVAX data for pancreatic cancer | 02-27-12 |
| GSK lassos rare disease program in Angiochem tie-up | 02-26-12 |
| Merck KGaA triggers restructuring as it pursues R&D turnaround | 02-27-12 |
| Study finds no (unique) industry bias in published trial results | 02-27-12 |
| FDA rejects Columbia Labs' gel to prevent preterm births | 02-27-12 |
| GSK lassos rare disease program in Angiochem tie up | 02-26-12 |
| GSK steps in to back Canadian vaccine project | 02-24-12 |
| Biotech VC climate warmer than some thought | 02-24-12 |
| Swiss biotech Actelion grabs rights to biologic in $68.5M deal | 02-24-12 |
| Russian biotech VC and Quintiles to join forces on pharma services startups | 02-24-12 |
| Forest Labs notches victory en route to FDA ruling on COPD drug | 02-24-12 |
| Chelsea Therapeutics surges on FDA panel nod for Northera | 02-24-12 |
| I'd like to add you to my professional network | 02-24-12 |
| $100M Russian biotech fund opens shop in Boston | 02-23-12 |
| New Zelboraf data shows big survival boost | 02-23-12 |
| Sanofi slams doors on Genzyme's Cambridge, U.K., outfit | 02-23-12 |
| UPDATE: Vivus soars after experts offer surprising support for weight drug | 02-22-12 |
| Vertex vows to race ahead with interferon-free combo for hep C | 02-23-12 |
| Satori snags $15M to fuel a trial on Alzheimer's drug | 02-23-12 |
| UPDATED: FDA panel overwhelmingly backs Vivus' diet drug | 02-22-12 |
| FDA panel overwhelmingly backs Vivus' diet drug | 02-22-12 |
| Genomics revolution ignites new M&A talk, showstoppers | 02-22-12 |
| Eisai co-developing cancer drug fueled by bacteria; U.S. trials launch soon | 02-22-12 |
| Collegium Pharma scores $22M round for abuse-preventing painkiller in Phase III | 02-22-12 |
| Venture backer makes $7M bet on cardio drug tech that could rival stents | 02-22-12 |
| Biotech VCs wait for big checks from string of buyout deals | 02-22-12 |
| Lee Hood startup grabs $10M to advance class of protein-capture agents | 02-22-12 |
| Pfizer amps up R&D partnering activity in China and India | 02-21-12 |
| Novartis snags preclinical hep C drug in $440M Enanta pact | 02-21-12 |
| FDA staffers advise agency to deny Chelsea's key drug | 02-21-12 |
| FDA raises cardio concerns on Forest's new COPD drug | 02-21-12 |
| Threshold shares spike on positive IIb data for pancreatic cancer drug | 02-21-12 |
| GTx shares tumble after clot threat forces hold on prostate cancer drug | 02-21-12 |
| Corcept skyrockets on FDA nod for rare disease drug | 02-17-12 |
| UPDATED: Gilead disappoints with relapse data in oral Hep C study | 02-17-12 |
| Vivo Ventures boosting biopharma bets in China with $375M fund | 02-17-12 |
| Observing Presidents Day | 02-17-12 |
| Pfizer grabs leg up in pursuit of rare disease drug win | 02-17-12 |
| Senator launches campaign for speedier approvals of targeted drugs | 02-17-12 |
| MIT scientists tout first human data on drug-delivery chips | 02-17-12 |
| FDA notes concerns about Vivus diet pill safety ahead of panel | 02-17-12 |
| Gilead disappoints with relapse data in oral Hep C study | 02-17-12 |
| Patent attorneys gear up as new biosimilar rules impact IP strategies | 02-16-12 |
| Sanofi's Viehbacher spotlights Big Pharma's new role creating biotechs | 02-16-12 |
| Alnylam identifies who's getting ax | 02-16-12 |
| J&J backs potential pain drugs derived from spider venom | 02-16-12 |
| Biotech startup Mnemosyne snags $5.4M A round for neuropsych R&D | 02-16-12 |
| Bionor surges as PhIIb study revives big hopes for HIV vaccine | 02-16-12 |
| Severino tapped to helm Amgen's global development team | 02-15-12 |
| Teva looks set for a new round of M&A deals | 02-15-12 |
| Tiny Atossa designs micro IPO to fund breast cancer work | 02-15-12 |
| Corporate VCs crowd into $43M round for Celladon | 02-15-12 |
| Hep C drug deal frenzy can't be slowed by growing doubts | 02-15-12 |
| Battered BioSante soars on FDA approval for testosterone gel | 02-15-12 |
| Pfizer R&D chief talks up chances for late-stage Alzheimer's drug | 02-14-12 |
| InnaVirVax nabs $4.9M in B round to advance HIV immunotherapy | 02-14-12 |
| Actelion hunts for answers about 120 deaths in key drug trial | 02-14-12 |
| Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix | 02-14-12 |
| Karo Bio walks away from Phase III cholesterol drug due to safety risks | 02-14-12 |
| Pioneering stem cell therapy mends damaged heart tissue in patients | 02-14-12 |
| The best of times, the worst of times? | 02-14-12 |
| DNA sequencing exposes new uses for Pfizer targeted cancer drugs | 02-13-12 |
| Chelsea shares nosedive on FDA's questions about key drug | 02-13-12 |
| GSK studies Chinese remedies to discover new drugs | 02-13-12 |
| Preclinical study triggers 'massive response' from desperate Alzheimer's patients | 02-13-12 |
